Ma, C. “Targeting IL23p19 Using Risankizumab for the Management of Moderate-to-Severely Active Crohn’s Disease: The Next Frontier?”. Canadian IBD Today, vol. 1, no. S05, May 2023, pp. 2–7, doi:10.58931/cibdt.2023.1S0510.